NClip

Acetylcholinesterase Inhibitors

4 min read

Acetylcholinesterase Inhibitors

Key Points

  • Acetylcholinesterase inhibitors block acetylcholine breakdown and increase cholinergic signaling at synapses.
  • Donepezil is used for cognitive symptoms in Alzheimer disease, and pyridostigmine-class therapy is used in myasthenia-gravis to improve neuromuscular signaling.
  • In Alzheimer regimens, donepezil is used across mild to severe stages, galantamine in mild-moderate disease, and rivastigmine in mild-severe disease.
  • Pyridostigmine is first-line maintenance therapy for MG; neostigmine is used IV in selected diagnostic and postoperative neuromuscular-blockade reversal pathways.
  • Give donepezil in the evening and with food to reduce GI upset.
  • Common adverse effects include GI upset, headache, dizziness, insomnia, fatigue, muscle cramps, and abnormal dreams.
  • Donepezil has a long half-life (about 70 hours), so dose changes and adverse effects may take days to stabilize.
  • Medication adherence support is often necessary because cognitive impairment can cause missed evening doses.
  • In MG pathways, acetylcholinesterase inhibitors are parasympathomimetic; overdose can precipitate cholinergic crisis with severe weakness and respiratory compromise.

Mechanism of Action

Acetylcholinesterase inhibitors block the enzyme that degrades acetylcholine. Increased acetylcholine concentration at the synaptic cleft can improve neuronal signal transmission in selected cognitive-disorder contexts.

Indications

  • Cognitive symptom management in Alzheimer disease (donepezil prototype in this source context).
  • Mild-moderate Alzheimer disease management with galantamine.
  • Mild-severe Alzheimer disease management with rivastigmine (including transdermal patch pathway).
  • Neuromuscular-junction support in myasthenia-gravis (pyridostigmine-class context) by increasing available acetylcholine.
  • Reversal of nondepolarizing neuromuscular blockade after surgery (neostigmine pathway with monitoring).

Reversible vs Irreversible Inhibition

  • Reversible AChE inhibitors (for example pyridostigmine, neostigmine) bind transiently and are the main therapeutic class for MG symptom control.
  • Irreversible AChE inhibitors have prolonged toxicity risk; pralidoxime is a cholinesterase reactivator used for poisoning by irreversible inhibitors.
  • Echothiophate (ophthalmic) is a rare irreversible option for glaucoma with limited use due to toxicity burden.

Nursing Considerations

  • Administer donepezil with food to minimize GI upset.
  • Schedule dosing in the evening, typically just before bedtime.
  • Monitor for GI intolerance, sleep-quality changes, and dizziness-related fall risk.
  • Monitor for bradycardia, heart block risk, and worsening respiratory status in clients with asthma/COPD.
  • Monitor liver enzyme trends when clinically indicated.
  • Use caution in peptic ulcer disease, active GI bleeding, and urinary or intestinal obstruction.
  • Assess medication adherence capacity; involve caregivers when cognitive impairment limits safe self-administration.
  • Review interaction risk with anticholinergics (for example first-generation antihistamines, conventional antipsychotics, TCAs) because they can blunt cholinergic benefit.
  • Reinforce additive bradycardia risk when combined with beta-blockers or digoxin.
  • For MG regimens, reinforce strict timing and monitor for worsening weakness, increased secretions, bradycardia, and respiratory decline after dosing.
  • Suspect cholinergic crisis when severe weakness escalates shortly after dose (often about 30-60 minutes); escalate emergently.
  • In MG care, time doses to optimize chewing/swallowing function around meals and monitor ptosis/fatigue patterns pre/post dose.
  • Keep atropine readily available when neostigmine is administered because excessive muscarinic effects can emerge rapidly.
  • For rivastigmine patch therapy, rotate sites and remove the old patch before applying a new one.

Adverse Effects

  • GI upset
  • Headache
  • Dizziness
  • Insomnia and reduced sleep quality
  • Fatigue
  • Muscle cramps
  • Nightmares or abnormal dreams
  • Possible liver enzyme elevation
  • Symptomatic bradycardia or AV block
  • Bronchoconstriction/increased secretions
  • Urinary urgency
  • Blurred distance vision and miosis
  • Seizure risk in susceptible clients
  • Cholinergic crisis pattern with severe muscarinic excess and respiratory compromise in overdose

Health Teaching

  • Take the medication every evening as prescribed.
  • If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose; do not double-dose.
  • Take with food to improve tolerance.
  • Report persistent GI symptoms, severe dizziness, sleep disturbance, or functional decline.
  • Report rash immediately during galantamine therapy because severe skin reactions are possible.
  • Families/caregivers should use reminder systems or supervised administration when memory impairment affects adherence.
  • For pyridostigmine ER products, do not crush or chew.
  • Do not stop therapy abruptly unless directed by the prescriber.
  • For rivastigmine patches: apply to clean, dry, hairless intact skin, rotate sites, avoid reusing the same site for 14 days, and wash hands after handling.
  • Do not use a damaged or cut rivastigmine patch, and use only one patch at a time.

Clinical Judgment Application

Clinical Scenario

A caregiver reports that a patient with Alzheimer disease misses evening donepezil doses and has worsening sleep disturbance.

  • Recognize Cues: Missed doses, cognitive-limitation adherence risk, and adverse sleep symptoms.
  • Analyze Cues: Inconsistent administration reduces therapeutic benefit and can worsen tolerability patterns.
  • Prioritize Hypotheses: Priority is safe medication adherence and adverse-effect mitigation.
  • Generate Solutions: Add caregiver-supervised evening routine, meal-linked dosing cue, and symptom log.
  • Take Action: Reinforce missed-dose rules and escalate persistent adverse effects for provider review.
  • Evaluate Outcomes: Dose adherence improves and sleep/GI symptoms become stable or improve.

Graph View